

May 1, 2026

BSE Limited

P J Towers,
Dalal Street,
Mumbai-400001

Code: 532321

National Stock Exchange of India Limited

Exchange Plaza,
C/1, Block G,
Bandra-Kurla Complex, Bandra (East),
Mumbai-400051

Code: Zyduslife

Sub.: Acquisition of shares of Aptitude Orthopedie, France, a simplified joint stock company

Ref.: Intimation under regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Listing Regulations") read with SEBI Master Circular dated January 30, 2026 ("the SEBI Circular")

Dear Sir / Madam,

With reference to the captioned subject, this is to inform that the Amplitude SAS ("**Amplitude**"), an indirect wholly owned subsidiary of Zydus Lifesciences Limited ("**the Company**"), has acquired 100% share capital of Aptitude Orthopedie, France, a simplified joint stock company ("**the Target Entity**").

Requisite details as required to be disclosed pursuant to the provisions of regulation 30 of the Listing Regulations read with para A of part A of Schedule of the Listing Regulations and para 1.1 of Annexure 18 of the SEBI Circular are provided in **Annexure-"1"**.

Yours faithfully,

For, **Zydus Lifesciences Limited**

Dhaval N. Soni

Company Secretary and Compliance Officer
Membership No. FCS7063

Encl.: As above



Annexure-“1”

Sr. No.	Particulars	Responses
1.	Name of the target entity, details in brief such as size, turnover etc.:	<p>Name of the Target Entity: Aptitude Orthopedie, a simplified joint-stock company having its registered office at 12 rue des Macareux, 35830 BETTON, France.</p> <p>Authorized and Paid-up Share Capital of the Target Entity: Euro 5,000 divided into 5000 equity shares of Euro 1 each.</p> <p>Turnover of the Target Entity: Euro 364,000, as per the audited financial statements as on June 30, 2025.</p>
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”:	<p>No, the acquisition would not fall within related party transaction.</p> <p>None of the promoter/ promoter group/ group companies have any interest in the Target Entity being acquired.</p>
3.	Industry to which the entity being acquired belongs:	The Target Entity specializes in the distribution of medical equipment.
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity):	The acquisition is intended to internalize commercial capabilities currently outsourced to third-party sales agents. By acquiring and integrating the Target Entity, Amplitude expects to eliminate ongoing commission and business-development fees, thereby reducing long-term selling and distribution costs.
5.	Brief details of any governmental or regulatory approvals required for the acquisition:	Not Applicable





Dedicated To Life

6.	Indicative time period for completion of the acquisition:	The transaction of acquisition is completed today i.e. April 30, 2026.
7.	Consideration - whether cash consideration or share swap or any other form and details of the same:	Cash consideration
8.	Cost of acquisition and/or the price at which the shares are acquired:	Euro 360,000 for acquisition of entire share capital of the Target Entity.
9.	Percentage of shareholding / control acquired and / or number of shares acquired:	5,000 shares of Euro 1 each fully paid-up representing 100% of the entire share capital of the Target Entity.
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief):	<p>The Target Entity was incorporated in 2016. It has signed an exclusive commercial agency agreement with Amplitude for the French department 14 and 50, excluding establishments which are shared with another exclusive agent, F.B.C MEDICAL.</p> <p>Turnover of last 3 years based on the audited financial statements:</p> <ul style="list-style-type: none">• FY2025: Euro 364,000• FY2024: Euro 380,000• FY2023: Euro 131,000

Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878

